News | July 17, 2014

Focal Healthcare to Develop New Targeted Prostate Biopsy, Therapy Devices

Michael McGuire, M.D., chief of urology at NorthShore University Health System in Chicago, is an early adopter of MRI fusion targeted biopsy and sits on the Clinical Advisory Board of Focal Healthcare.

July 17, 2014 — Focal Healthcare was founded as a spin-off company out of the Centre for Imaging Technology Commercialization (CIMTEC). Focal is developing and marketing MRI (magnetic resonance imaging)-ultrasound fusion biopsy and therapy systems that have strong potential to become the new gold standard in prostate care by capitalizing on CIMTEC's intellectual property, as well as its extensive technology development and commercialization expertise in the medical imaging field.

The current paradigm for prostate cancer care has remained unchanged for more than 25 years. It is well accepted that prostate cancer is fundamentally over-treated either through irradiating or surgically removing the entire prostate; both options include significant risk for life-altering side effects. This is due to the inherent limitations of ultrasound image quality, which is currently used to guide urologists in extracting random biopsy samples from the prostate. Oftentimes, this method leads to the detection of insignificant cancers or the misdiagnosis of serious cancers.

Michael McGuire, chief of urology at NorthShore University Health System in Chicago believes strongly in Focal Healthcare's products and is one of three highly respected experts in the prostate world who sits on its Clinical Advisory Board.

"I am pleased to be able to play a role in the success of Focal's game-changing prostate therapy products by testing the equipment and providing valuable feedback," McGuire said. "The superior capabilities of their products will enable urologists to accurately record biopsy locations for active surveillance of prostate cancer, as well as allow us to appropriately administer therapy, which will significantly reduce the incidence of over-treatment and improve quality of life for our patients."

Focal Healthcare has several patents, a management and development team with more than 30 years of experience in the prostate imaging and clinical device development space, access to validated underlying science and products with portability, cost effectiveness and ease of use.

Related Content

Novel Technique May Significantly Reduce Breast Biopsies
News | Breast Biopsy Systems | January 17, 2019
A novel technique that uses mammography to determine the biological tissue composition of a tumor could help reduce...
Brachytherapy Alone Superior Treatment for Intermediate-Risk Prostate Cancer
News | Brachytherapy Systems | January 04, 2019
Patient-reported outcomes (PROs) indicated a significantly different clinician and patient-reported late toxicity...
Immune Inflammatory Levels Linked to Disease-Free Survival in Prostate Cancer
News | Prostate Cancer | November 19, 2018
Data from a validation study of a high-risk prostate cancer trial suggests that higher levels of pretreatment...
Hypofractionated Radiation Provides Same Prostate Cancer Outcomes as Conventional Radiation
News | Intensity Modulated Radiation Therapy (IMRT) | October 31, 2018
An analysis led by researchers at Philadelphia’s Fox Chase Cancer Center found treating localized prostate cancer with...
Prostate Brachytherapy Shows Low Incidence of Short-Term Complications
News | Brachytherapy Systems | October 31, 2018
A new analysis of nearly 600 men receiving brachytherapy for prostate cancer shows overall procedure-related...
Biomarker blood test accurately confirms remission in non-smoker with HPV-associated oral cancer. ASTRO 2018 #ASTRO2018 #ASTRO #ASTRO18

Biomarker blood test accurately confirms remission in non-smoker with HPV-associated oral cancer.

News | Radiation Oncology | October 30, 2018
October 30, 2018 — A highly sensitive blood test that detects minute traces of cancer-specific DNA has been shown to
Prostate Radiotherapy Outcomes Better for African-Americans Than Caucasian Patients according to a study presented at ASTRO 2018. #ASTRO #ASTRO18 #ASTRO2018
Feature | Prostate Cancer | October 30, 2018
October 30, 2018 — While popular beliefs and population data suggest that African-American men are at higher risk of
Combined Therapy Including Pelvic Lymph Node Radiation Provides Significant Benefit for Prostate Cancer Patients - late breaking study presented at ASTRO 2018.
News | Prostate Cancer | October 22, 2018
The first report of a large, international clinical trial shows that, for men who show signs of...